DocWire News Editors

DocwireNews

Biologic therapies have transformed the management of inflammatory arthritis (IA).&nbsp;When using&nbsp;these type of therapies, patients can benefit from a more targeted approach and remission is much more likely. However, there are risks when using&nbsp;these types of biologic therapies.&nbsp;In a study published in&nbsp;Rheumatology,&nbsp;this guideline supersedes the previous BSR/BHPR anti-TNF, rituximab,&nbsp;and tocilizumab&nbsp;guidelines and has been developed in line with the BSR Guidelines Protocol.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Read the brand new <a href="https://twitter.com/RheumatologyUK?ref_src=twsrc%5Etfw">@RheumatologyUK</a> biologic <a href="https://twitter.com/hashtag/DMARD?src=hash&amp;ref_src=twsrc%5Etfw">#DMARD</a> safety guidelines in inflammatory <a href="https://twitter.com/hashtag/arthritis?src=hash&amp;ref_src=twsrc%5Etfw">#arthritis</a> online now <a href="https://t.co/VV8yBlwroY">https://t.co/VV8yBlwroY</a> <a href="https://twitter.com/hashtag/DMARDs?src=hash&amp;ref_src=twsrc%5Etfw">#DMARDs</a>
&mdash; Rheumatology &amp; Rheumatology Advances in Practice (@RheumJnl) <a href="https://twitter.com/RheumJnl/status/1032183205766619141?ref_src=twsrc%5Etfw">August 22, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The first guidelines&nbsp;on&nbsp;safety of anti-TNF agents in&nbsp;rheumatoid arthritis (RA) were released by the British Society of Rheumatology&nbsp;in 2001.&nbsp;The guidelines were updated in 2005, and then 2010.&nbsp;According to the study, these guidelines covered the indications and precautions for the use of anti-TNF agents, and the action that should be taken in the case of an adverse event.&nbsp;As these guidelines are updated, the focus is to provide information on&nbsp;evidence-based recommendations for the safe use of biologic therapies in adults (aged &gt;18 years).&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Just published: our new NICE accredited guideline 'Biologic DMARD safety guideline in <a href="https://twitter.com/hashtag/inflammatory?src=hash&amp;ref_src=twsrc%5Etfw">#inflammatory</a> <a href="https://twitter.com/hashtag/arthritis?src=hash&amp;ref_src=twsrc%5Etfw">#arthritis</a>' is now available to view here. <a href="https://twitter.com/RheumJnl?ref_src=twsrc%5Etfw">@RheumJnl</a> <a href="https://twitter.com/NICEComms?ref_src=twsrc%5Etfw">@NICEcomms</a> <a href="https://t.co/dDjf7rznF6">https://t.co/dDjf7rznF6</a>
&mdash; BSR (@RheumatologyUK) <a href="https://twitter.com/RheumatologyUK/status/1032183621887635456?ref_src=twsrc%5Etfw">August 22, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>There are&nbsp;several specific safety areas&nbsp;discussed in the guidelines, including:&nbsp;<ul>
<li>The&nbsp;recommendations for baseline screening prior to initiation&nbsp;</li>
<li>The recommendations for monitoring&nbsp;</li>
<li>The implications of co-morbid disease and ageing&nbsp;</li>
<li>Vaccinations and the management of biologic therapies in specific situations such as infection&nbsp;</li>
<li>Malignancy and the peri-operative window&nbsp;</li>
</ul><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
"It is essential that data on the safety of these products continue to be captured." New <a href="https://twitter.com/RheumatologyUK?ref_src=twsrc%5Etfw">@RheumatologyUK</a> biologic DMARD safety guidelines in inflammatory arthritis.<a href="https://t.co/PPBtLGZel5">https://t.co/PPBtLGZel5</a><a href="https://twitter.com/hashtag/BSR_PsA?src=hash&amp;ref_src=twsrc%5Etfw">#BSR_PsA</a> <a href="https://twitter.com/UoAEpi?ref_src=twsrc%5Etfw">@UoAEpi</a> <a href="https://twitter.com/BSRBR_RA?ref_src=twsrc%5Etfw">@BSRBR_RA</a>
&mdash; Gareth Jones (@hteraG_senoJ) <a href="https://twitter.com/hteraG_senoJ/status/1032258255647633408?ref_src=twsrc%5Etfw">August 22, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Check out&nbsp;an article on&nbsp;if tumor necrosis factor inhibitors (TNFi) treatment in rheumatoid arthritis (RA) is really associated with an&nbsp;<a class="Hyperlink SCXW94766079" href="https://proddocwire.wpengine.com/docwire-pick/tnfi-cancer-recurrence-ra/" target="_blank" rel="noopener noreferrer">increased risk for cancer recurrence</a>.&nbsp;&nbsp;SOURCE:&nbsp;<a href="https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/key208/5076446">Rheumatology&nbsp;</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

The British Society of Rheumatology Releases Updated Anti-TNF Agent Guidelines

Rheumatology

Biologic therapies have transformed the management of inflammatory arthritis (IA). When using these type of therapies, patients can benefit from a more targeted approach and ...